A dire picture for HIV/Aids funding emerged at the 12th South African AIDS Conference, raising the call for resilience, adapting and also for government to raise its game, reports Ufrieda Ho.
A new HIV prevention jab has the potential to bring an end to the AIDS epidemic. But a lack of ambition and unjustifiable secrecy over pricing is holding it back, argue three leading health activists.
A child-friendly formulation of the antiretroviral drug dolutegravir was first included in the country’s HIV treatment guidelines in 2023. New estimates suggest that most children aged one to four living with HIV have now been switched to the drug, reports Elri Voigt.
The health department has plans to roll out lenacapavir, a twice-yearly HIV prevention injection, in a select group of public sector clinics by April 2026. Meanwhile, little progress has been made towards rolling out a two-monthly prevention injection, despite the four-year head start this product had on lenacapavir. Catherine Tomlinson reports.
From anti-apartheid activist to top rated researcher, Professor Rachel Jewkes has spent her career trying to make the world a better place for women. Elri Voigt spoke to her about her journey to South Africa from the United Kingdom and how she became one of the country’s leading researchers on gender-based violence.
The obesity epidemic will hit South Africa hard on top of our high HIV burden, but advocate researcher and scientist Dr Nomathemba Chandiwana says she is ready to fight back harder. She speaks to Ufrieda Ho about her journey from working in state hospitals to transitioning into obesity medicine, and her move to Cape Town.
In response to US funding cuts for South African health services and research projects, National Treasury has provided the National Department of Health with hundreds of millions of rands in emergency funds. Spotlight and GroundUp look at how precisely the government intends to spend this money.
An HIV prevention pill that could provide a month of protection per tablet has been given the green light to proceed to pivotal trials to test its efficacy. Elri Voigt reports on new findings on the pill that were presented at the International AIDS Conference.
Spotlight and GroundUp published a two-part exposé showing how US aid cuts led to the deaths of children in Mozambique. Here, Jesse Copelyn considers what led to this tragedy and who should bear responsibility for it.
South Africa is staging a sequel to Mbeki-era denialism, only this time, the science, solutions, and costs are clearer, argues Professor Francois Venter.
TB can be cured, but ridding the body of the bug often takes many months and usually requires taking four or more different medicines. In this Spotlight special briefing, Elri Voigt zooms in on what makes the TB bacterium so hard to beat.
South Africa still lacks an action plan after the withdrawal of US aid for HIV and related health services. But when funds do arrive, how will they be managed? Russell Rensburg suggests the answer may lie in the District Health Programme Grant.
